Adbry Price in India

Medicinal Uses

Tralokinumab-ldrm injection is an interleukin-13 antagonist indicated for the treatment of moderate-to-severe atopic dermatitis in adult patients. This is for individuals whose condition remains inadequately controlled with topical prescription therapies or when these therapies are not advisable. Tralokinumab-ldrm can be used in combination with or without topical corticosteroids.

Recommended Dosage:

Before starting Tralokinumab-ldrm treatment, ensure all age-appropriate vaccinations as recommended by current immunization guidelines are completed. The recommended dosage includes an initial dose of 600 mg (four injections of 150 mg each), followed by 300 mg (two 150 mg injections) administered every other week. For patients below 100 kg achieving clear or almost clear skin after 16 weeks, a dosage of 300 mg every 4 weeks may be considered. Tralokinumab-ldrm is administered through subcutaneous injection.

Warnings and Precautions:

Hypersensitivity: Anaphylaxis and angioedema have been reported after Tralokinumab-ldrm administration. Discontinue Tralokinumab-ldrm in case of hypersensitivity reactions.

Conjunctivitis and Keratitis: Patients should promptly report any new or worsening eye symptoms to their healthcare provider.

Parasitic (Helminth) Infections: Address pre-existing helminth infections before starting Tralokinumab-ldrm. If infections occur during treatment and don't respond to anti-helminth treatment, discontinue Tralokinumab-ldrm until the infection resolves.

Risk of Infection with Live Vaccines: Avoid the use of live vaccines while on Tralokinumab-ldrm treatment.

Documentation & Availability in India:

If you are considering the import of Tralokinumab to India, please be aware that Tralokinumab-ldrm can be imported by patients or government hospitals solely in the name of the patients. The following documentation is essential for the successful import of this medication:

Required Documentation for Import:

• A valid prescription from a qualified medical practitioner.
• Diagnostic reports of the patient.
• Government-issued identification proof for the patient, as recognized by the Government of India.

Order Confirmation Process: 

• The order for Elahere will be confirmed upon the receipt of the following documents:
• A valid prescription from a qualified doctor.
• An import permit, if applicable.

Availability of Tralokinumab-ldrm in India: 

Tralokinumab is classified as a prescription pharmaceutical drug. Consequently, it legally requires a medical prescription to be dispensed. Indian Pharma Network (IPN) specializes in facilitating the import of cancer medicines through named patient supply (NPS), ensuring transparency and authenticity by sourcing from reputable suppliers in the USA, Canada, Europe, and Australia.

Tralokinumab-ldrm can be made accessible to patients, doctors, and hospitals in various cities across India, including but not limited to Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, and Pune. To confirm an order, a valid prescription from a doctor and an import permit will be required.

IPN (Indian Pharma Network) is dedicated to facilitating the supply of Tralokinumab-ldrm (prescription medicines) to locations both within India and worldwide, while adhering to relevant legal requirements.

For inquiries regarding the price of Tralokinumab-ldrm in India and to initiate the ordering process, please reach out to us through the following contact details:

Our commitment lies in assuring quality and timely delivery to meet the healthcare needs of patients and medical professionals across the globe.

Sourcing & Delivery: Indian Pharma Network is proficient in sourcing Tralokinumab-ldrm from around the world and ensuring efficient delivery to patients. We provide worldwide access to the best available treatments and expedite prescription dispensing and delivery, with all prescriptions being dispensed and scrutinized by registered pharmacists before dispatching them to the patient's address, exclusively from New Delhi, India.

What is Tralokinumab-ldrm used for?

Tralokinumab-ldrm is an interleukin-13 antagonist prescribed for the treatment of moderate-to-severe atopic dermatitis in adults. It's specifically for patients whose condition isn't adequately controlled with topical prescription therapies or when using those therapies isn't advisable.

How is Tralokinumab-ldrm administered?

Tralokinumab-ldrm is administered through subcutaneous injection. The typical dosage includes an initial dose of 600 mg (four injections of 150 mg each), followed by a maintenance dose of 300 mg (two 150 mg injections) every other week. Some patients achieving clearer skin after 16 weeks might have their dosage adjusted to 300 mg every 4 weeks.

Can Tralokinumab-ldrm be used in combination with other medications?

Tralokinumab-ldrm can be used with or without topical corticosteroids. However, it is not recommended to be used in combination with other JAK inhibitors or certain immunosuppressants.

Are there any conditions where Tralokinumab-ldrm should not be used?

Tralokinumab-ldrm should not be used in individuals with a known hypersensitivity to tralokinumab-ldrm or any components present in the medication.

What precautions should be taken while using Tralokinumab-ldrm?

Some precautions include careful monitoring for hypersensitivity reactions, prompt reporting of new or worsening eye symptoms, treating pre-existing helminth infections before starting Tralokinumab-ldrm, avoiding live vaccines during treatment, and regular check-ups and tests to monitor health during treatment.